# BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Source: https://onco.cc/trials/nct07625644/  
OnCo record `nct07625644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Atezolizumab, Carboplatin, Etoposide in small-cell lung cancer, run by SystImmune Inc., now recruiting.

## Summary

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) is a phase 3 interventional study registered as NCT07625644 by SystImmune Inc., with 550 participants planned, started 2026-08-04 and due to reach its primary completion in 2030-01. Interventions recorded: BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin. Conditions listed: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07625644
- Phase: 3
- Setting: A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer
- Sponsor: SystImmune Inc.
- Enrolled: 550

## Sources

- ClinicalTrials.gov NCT07625644: https://clinicaltrials.gov/study/NCT07625644

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07625644.json